| abstract |
The present invention relates to an HDM2-p53 interaction inhibitor drug (S)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro- Phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one [HDM201] and anti-TIM-3 antibody molecules as TIM-3 inhibitors. The present invention also relates to the use of said combination in the treatment of cancer, in particular hematological tumors. The present invention also relates to dosages and dosing regimens associated with such combination cancer treatment. |